Great research starts with great data.

Learn More
More >
Patent Analysis of

2H-chromene derivatives as analgesic agents

Updated Time 12 June 2019

Patent Registration Data

Publication Number

US9999613

Application Number

US15/323110

Application Date

10 June 2015

Publication Date

19 June 2018

Current Assignee

OBSHESTVO S OGRANICHENNOI OTVETSVENNOSTJU "LEOFORS"

Original Assignee (Applicant)

OBSHESTVO S OGRANICHENNOI OTVETSVENNOSTJU "LEOFORS"

International Classification

A61K31/381

Cooperative Classification

A61K31/381,A61K31/353

Inventor

KHAID, EKATERINA VLADIMIROVNA,PAVLOVA, ALLA VIKTOROVNA,MIKHAL'CHENKO, OKSANA STANISLAVOVNA,KORCHAGINA, DINA VLADIMIROVNA,TOLSTIKOVA, TATIANA GENRIHOVNA,VOLCHO, KONSTANTIN PETROVICH,KHAZANOV, VENIAMIN ABRAMOVICH,SALAKHUTDINOV, NARIMAN FARIDOVICH

Patent Images

This patent contains figures and images illustrating the invention and its embodiment.

US9999613 2H-chromene derivatives analgesic agents 1 US9999613 2H-chromene derivatives analgesic agents 2 US9999613 2H-chromene derivatives analgesic agents 3
See all images <>

Abstract

The invention relates to the use of the compound of general formula 1 or its spatial isomers

as an analgesic drug. The compounds have high activity, low toxicity, may be used in medicine.

Read more

Claims

1. A method of reducing pain in a subject, comprising administration of a compound of formula 1, or a stereoisomer thereof, to the subject wherein R1, R2, and R3 are identical or different, and are selected from the group consisting of a hydrogen atom, an alkyl group, a nitro group, and a halogen.

2. The method of claim 1, wherein one or more of R1, R2, and R3 is an alkyl group, a nitro group, or a halogen.

Read more

Claim Tree

  • 1
    1. A method of reducing pain in a subject, comprising
    • administration of a compound of formula 1, or a stereoisomer thereof, to the subject wherein R1, R2, and R3 are identical or different, and are selected from the group consisting of a hydrogen atom, an alkyl group, a nitro group, and a halogen.
    • 2. The method of claim 1, wherein
      • one or more of R1, R2, and R3 is an alkyl group, a nitro group, or a halogen.
See all independent claims <>

Description

FIELD OF THE INVENTION

The invention relates to the field of medicine, specifically, to drugs having analgesic effect.

BACKGROUND OF THE INVENTION

Analgesic drugs are known, that are nonnarcotic analgesics by their mechanism of action, such as acetylsalicylic acid, metamizole and others [1]. Data on activity in acetic acid induced writhing test (ED50) and acute toxicity (LD50) of the known drugs are presented in [2] and in Table 1.


TABLE 1
Toxicity and analgesic action of the known drugs [2].
Drug
ED50, mg/kg
LD50, mg/kg
Acetylsalicylic acid
155
1600
Metamizole
55
3300
Sodium diclofenac
5
370

The disadvantage of acetylsalicylic acid is low activity and gastrointestinal toxicity; metamizole may induce hematopoiesis disorders, up to agranulocytosis.

Diclofenac sodium [3] was chosen as a prototype.

The disadvantages of sodium diclofenac are adverse gastrointestinal effects (gastrointestinal toxicity).

DESCRIPTION OF THE INVENTION

The goal of the invention is the development of new low toxic drugs possessing analgesic activity.

The goal is achieved by using the compounds of general formula 1

where R1, R2, R3, may be identical or different; and may be a hydrogen atom, alkyl group, nitro group, halogen, as an analgesic drug, including their spatial isomers, including optically active isomers.

Compound 1a (R1═R2═R3═H) was earlier synthesized by interaction of isopulegol 2 with thiophene-2-carbaldehyde in the presence of modified montmorillonite H-K10 clay under microwave radiation with 50% yield [4].

The derivatives of compound 1a, containing substituents in the heteroaromatic ring, weren't earlier described in the literature.

We have demonstrated that compound 1a may be produced with yield 78% by reaction of isopulegol 2 with thiophene-2-carbaldehyde in the presence of commercially available montmorillonite K10 clay without its prior chemical modification and in the absence of microwave radiation by simply keeping the reaction mixture without solvent during 1-2 hrs.

The derivatives of compound 1a, containing substituents in the heteroaromatic ring, can be synthesized by reaction of isopulegol 2 with substituted thiophene-2-carbaldehydes in the presence of K10 clay.

To produce compounds of general formula 1 as different stereoisomers, including optically active isomers, different spatial isomers of compound 2, including optically active isomers, may be used as raw materials.

Analgesic activity of compounds of general formula 1 was studied in the model of visceral pain <<acetic acid induced writhing test>> and thermal irritation test <<hot plate>> in white outbred mice of body mass 20-22 g in groups of 8 animals each after single administration in 1÷20 mg/kg doses.

Acetic acid induced writhing test was performed by intraperitoneal administration of 0.1 ml of 0.75% acetic acid to an animal. Activity was assessed by the quantity of writhing movements during 3 min.

Hot plate test characterizes thermal stimulus. The animals were placed on a copper plate, T=54° C. The effect was assessed by the duration of stay of the animal on the hot plate before the first vocalization.

It was determined, that compounds of general formula 1 in 10 mg/kg dose have potent analgesic activity in acetic acid induced writhing test, and compounds 1a (R1═R2═R3═H) and 1d (R1═H, R2═Br, R3═H) are more effective than sodium diclofenac, taken in the same dose (Table 2).


TABLE 2
Analgesic activity of compounds of general formula 1 in acetic
acid induced writhing test in 10 mg/kg dose.
Writhes, quantity
Pain reduction,
Compound
Control
Agent
%a
1a
R1 = R2 = R3 = H
 9.6 ± 0.9
4.3 ± 1.1
55**
1b
R1 = R2 = H, R3 = Me
10.9 ± 0.5
7.0 ± 0.6
36***
1c
R1 = Me, R2 = R3 = H
10.9 ± 0.5
6.6 ± 0.5
39***
1d
R1 = H, R2 = Br, R3 = H
 9.6 ± 0.9
3.6 ± 1.5
63**
1e
R1 = Br, R2 = R3 = H
 9.6 ± 0.9
6.3 ± 1.2
34*
1f
R1 = NO2, R2 = R3 = H
11.1 ± 0.7
7.5 ± 1.2
32*
Sodium diclofenac
10.1 ± 1.9
5.0 ± 1.1
50***
a% pain reduction = (tcontrol − texp)/tcontrol · 100%
*P < 0.05; **P < 0.01; ***P < 0.001 compared to control

Data on analgesic activity in hot plate test is shown in Table 3. Reliable analgesic activity was observed for compound 1a (R1═R2═R3═H).


TABLE 3
Analgesic compounds of general formula 1 in hot plate
test in 10 mg/kg doses.
Hot plate, sec.
Compound
Control
Agent
Protection, %a
1a
R1 = R2 = R3 = H
9.8 ± 0.8
13.1 ± 1.2
 34*
1b
R1 = R2 = H, R3 = Me
18.4 ± 2.1 
12.8 ± 1.7
1c
R1 = Me, R2 = R3 = H
18.4 ± 2.1 
17.4 ± 2.4
1d
R1 = H, R2 = Br, R3 = H
9.8 ± 0.8
13.6 ± 1.7
39
1e
R1 = Br, R2 = R3 = H
9.8 ± 0.8
11.6 ± 1.0
18
1f
R1 = NO2, R2 = R3 = H
12.1 ± 1.3 
14.5 ± 1.6
20
Sodium diclofenac
9.6 ± 1.6
15.6 ± 2.4
 62**
a% protection = (texp − tcontrol)/tcontrol · 100%
*P < 0.05; **P < 0.01; *** P < 0.001 compared to control

Dose dependent effect of compound 1a, demonstrating high activity in both tests, was studied (Table 4). Data obtained show, that compound 1a has potent analgesic activity in both tests even in 1 mg/kg dose, being as effective as the reference drug sodium diclofenac in 10 mg/kg dose (Tables 2 and 3).


TABLE 4
Analgesic activity of compound 1a in acetic acid writhing
test and hot plate test in different doses.
Dose,
Writhes, quantity
Hot plate, sec.
mg/
Agent
Agent
kg
Control
(pain reduction, %)a
Control
(protection, %)b
20
11.0 ± 0.7 
8.3 ± 0.5 (25)**
10.7 ± 1.4
16.0 ± 2.6 (50) 
10
9.6 ± 0.9
4.3 ± 1.1 (55)**
 9.8 ± 0.8
13.1 ± 1.2 (34*)
5
8.4 ± 0.6
4.9 ± 1.0 (42)**
10.4 ± 1.2
16.3 ± 1.6 (57)*
1
8.4 ± 0.6
 2.4 ± 0.8 (71)***
10.4 ± 1.2
16.5 ± 1.9 (59)*
0.5
10.1 ± 0.7 
7.4 ± 1.3 (27) 
15.8 ± 1.6
20.3 ± 2.2 (28) 
a% pain reduction = (tcontrol − texp)/tcontrol · 100%
b% protection = (texp − tcontrol)/tcontrol · 100%
*P < 0.05; **P < 0.01; ***P < 0.001 compared to control

Acute toxicity of compound 1a was studied in white outbred mice, body mass 20-22 g, after single intragastric administration using Kerber method. It was demonstrated, that compound 1a is a moderately toxic compound: LD50 is over 1500 mg/kg, while therapeutic index (IS50) is over 1500. Thus, compound 1a is considerably less toxic than sodium diclofenac (LD50 370 mg/kg [2]) and has much better therapeutic index (IS50 of sodium diclofenac is 74 [2]).

Based on the aforementioned data, it can be concluded, that compounds of general formula 1 exhibit potent analgesic action in acetic acid induced writhing test. Compound 1a combines potent analgesic activity in acetic acid induced writhing test and hot plate test with low acute toxicity.

After detailed pharmacological studies, compounds of general formula 1 can used in pure form as well as a component of novel, low toxic, highly effective analgesic dosage forms.

The invention is illustrated by the following examples.

Example 1. Synthesis of 4,7-dimethyl-2-(thiophene-2-yl)octahydro-2H-chromene-4-ol 1a

A solution of 0.29 g thiophene-2-carbaldehyde in 3 ml CH2Cl2 was added to a suspension of 1.3 g of K10 clay in 5 ml CH2Cl2, then a solution of 0.400 g isopulegol 2 in 3 ml CH2Cl2 was added. The solvent was evaporated and the reaction mixture was kept at room temperature during 60 min. Then 10 ml of EtOAc was added, the catalyst was filtered and the solvent was evaporated. The resulting mixture was separated at a column with 13 g silica gel (eluent: solution of 0 to 100% ethyl acetate in hexane). 0.543 g (yield 78%) of compound 1a was obtained. NMR 1H spectrum of compound 1a corresponds to the spectrum, published in the literature [4].

Example 2. Synthesis of 4,7-dimethyl-2-(3-methylthiophene-2-yl)octahydro-2H-chromene-4-ol 1b

Similar to Example 1, interaction of 0.300 g isopulegol 2 with 0.25 g 3-methylthiophene-2-carbaldehyde in the presence of 1.1 g K10 clay during 120 min resulted in 0.381 g (yield 70%) of compound 1b.

Spectrum NMR 1H (CDCl3): 0.88-0.97 (m, 1H, Ha-8); 0.92 (d, J (16, 9a)=6.6 Hz, 3H, H-16); 1.03 (dddd, J (7a, 7e)=J (7a, 8a)=12.8 Hz, J (7a, 6a)=12.1 Hz, J (7a, 8e)=3.3 Hz, 1H, Ha-7); 1.11 (ddd, J (10a, 10e)=J (10a, 9a)=12.2 Hz, J (10a, 1a)=10.8 Hz, 1H, Ha-10); 1.28 (d, J (15, 4a)=0.7 Hz, 3H, H-15); 1.31 (ddd, J (6a, 7a)=12.1 Hz, J (6a, 1a)=10.2 Hz, J (6a, 7e)=3.3 Hz, 1H, Ha-6); 1.40-1.53 (m, 2H, Ha-9, OH); 1.72 (ddddd, J (8e, 8a)=12.9 Hz, J (8e, 7a)=J (8e, 9a)=J (8e, 7e)=3.3 Hz, J (8e, 10e)=2.0 Hz, 1H, He-8); 1.85 (ddq, J (4a, 4e)=12.7 Hz, J (4a, 3a)=11.7 Hz, J (4a, 15)=0.7 Hz, 1H, Ha-4); 1.91-1.97 (m, 1H, He-7); 1.95 (dd, J (4e, 4a)=12.7 Hz, J (4e, 3a)=2.4 Hz, 1H, He-4); 1.99 (dm, J (10e, 10a)=12.2 Hz, 1H, He-10); 2.19 (s, 3H, H-17); 3.26 (ddd, J (1a, 10a)=10.8 Hz, J (1a, 6a)=10.2 Hz, J (1a, 10e)=4.3 Hz, 1H, Ha-1); 4.71 (dd, J (3a, 4a)=11.7 Hz, J (3a, 4e)=2.4 Hz, 1H, Ha-3); 6.75 (d, J (13, 12)=5.0 Hz, 1H, H-13); 7.09 (d, J (12, 13)=5.0 Hz, 1H, H-12). Spectrum NMR 13C (CDCl3): 77.63 (d, C-1); 71.09 (d, C-3); 49.70 (t, C-4); 70.64 (s, C-5); 51.91 (d, C-6); 22.94 (t, C-7); 34.26 (d, C-9); 41.32 (t, C-10); 138.34 (s, C-11); 122.92 (d, C-12); 129.72 (d, C-13); 133.29 (s, C-14); 21.09 (q, C-15); 22.03 (q, C-16); 13.63 (q, C-17). HR-MS: 280.1488 (M+, C16H24O2S+; calc. 280.1492).

Example 3. Synthesis of 4,7-dimethyl-2-(5-methylthiophene-2-yl)octahydro-2H-chromene-4-ol 1c

Similar to Example 1, interaction of 0.300 g isopulegol 2 with 0.25 g 5-methylthiophene-2-carbaldehyde in the presence of 1.1 g K10 clay during 120 min resulted in 0.386 g (yield 71%) of compound 1c.

Spectrum NMR 1H (CDCl3): 0.87-0.96 (m, 1H, Ha-8); 0.92 (d, J (16, 9a)=6.6 Hz, 3H, H-16); 1.02 (dddd, J (7a, 7e)=J (7a, 8a)=12.8 Hz, J (7a, 6a)=12.2 Hz, J (7a, 8e)=3.3 Hz, 1H, Ha-7); 1.09 (ddd, J (10a, 10e)=J (10a, 9a)=12.3 Hz, J (10a, 1a)=10.8 Hz, 1H, Ha-10); 1.25 (d, J (15, 4a)=0.8 Hz, 3H, H-15); 1.28 (ddd, J (6a, 7a)=12.2 Hz, J (6a, 1a)=10.2 Hz, J (6a, 7e)=3.3 Hz, 1H, Ha-6); 1.39-1.52 (m, 2H, Ha-9, OH); 1.72 (ddddd, J (8e, 8a)=12.8 Hz, J (8e, 7a)=J (8e, 9a)=J (8e, 7e)=3.3 Hz, J (8e, 10e)=2.0 Hz, 1H, He-8); 1.86 (ddq, J (4a, 4e)=12.7 Hz, J (4a, 3a)=11.7 Hz, J (4a, 15)=0.8 Hz, 1H, Ha-4); 1.93 (dddd, J (7e, 7a)=12.8 Hz, J (7e, 6a)=J (7e, 8a)=J (7e, 8e)=3.3 Hz, 1H, He-7); 1.99 (dm, J (10e, 10a)=12.3 Hz, 1H, He-10); 2.01 (dd, J (4e, 4a)=12.7 Hz, J (4e, 3a)=2.2 Hz, 1H, He-4); 2.42 (d, J (17, 13)=1.1 Hz, 3H, H-17); 3.24 (ddd, J (1a, 10a)=10.8 Hz, J (1a, 6a)=10.2 Hz, J (1a, 10e)=4.3 Hz, 1H, Ha-1); 4.59 (dd, J (3a, 4a)=11.7 Hz, J (3a, 4e)=2.2 Hz, 1H, Ha-3); 6.56 (dq, J (13, 14)=3.4 Hz, J (13, 17)=1.1 Hz, 1H, H-13); 6.73 (d, J (14, 13)=3.4 Hz, 1H, H-14). Spectrum NMR 13C (CDCl3): 77.43 (d, C-1); 72.54 (d, C-3); 49.58 (t, C-4); 70.69 (s, C-5); 51.89 (d, C-6); 22.93 (t, C-7); 34.26 (t, C-8); 31.38 (d, C-9); 41.35 (t, C-10); 142.89 (s, C-11); 139.12 (s, C-12); 124.26 (d, C-13); 123.50 (d, C-14); 21.17 (q, C-15); 22.04 (q, C-16); 15.16 (q, C-17). HR-MS: 280.1491 (M+, C16H24O2S+; calc. 280.1492).

Example 4. Synthesis of 4,7-dimethyl-2-(4-bromothiophene-2-yl)octahydro-2H-chromene-4-ol 1d

Similar to Example 1, interaction of 0.300 g isopulegol 2 with 0.37 g 4-bromothiophene-2-carbaldehyde in the presence of 1.4 g K10 clay during 120 min resulted in 0.499 g (yield 74%) of compound 1d.

Spectrum NMR 1H (CDCl3): 0.87-0.96 (m, 1H, Ha-8); 0.93 (d, J (16, 9a)=6.6 Hz, 3H, H-16); 1.02 (dddd, J (7a, 7e)=J (7a, 8a)=12.8 Hz, J (7a, 6a)=12.1 Hz, J (7a, 8e)=3.2 Hz, 1H, Ha-7); 1.10 (ddd, J (10a, 10e)=J (10a, 9a)=12.2 Hz, J (10a, 1a)=11.1 Hz, 1H, Ha-10); 1.26 (d, J (15, 4a)=0.7 Hz, 3H, H-15); 1.29 (ddd, J (6a, 7a)=12.1 Hz, J (6a, 1a)=10.1 Hz, J (6a, 7e)=3.2 Hz, 1H, Ha-6); 1.39-1.50 (m, 1H, Ha-9); 1.56 (br.s, OH); 1.72 (dm, J (8e, 8a)=12.8 Hz, others J<3.5 Hz, 1H, He-8); 1.82 (ddq, J (4a, 4e)=12.7 Hz, J (4a, 3a)=11.7 Hz, J (4a, 15)=0.7 Hz, 1H, Ha-4); 1.93 (dddd, J (7e, 7a)=12.8 Hz, J (7e, 6a)=J (7e, 8a)=J (7e, 8e)=3.2 Hz, 1H, He-7); 1.99 (dddd, J (10e, 10a)=12.8 Hz, J (10e, 1a)=4.3 Hz, J (10e, 9a)=3.7 Hz, J (10e, 8e)=2.0 Hz, 1H, He-10); 2.01 (dd, J (4e, 4a)=12.7 Hz, J (4e, 3a)=2.2 Hz, 1H, He-4); 3.26 (ddd, J (1a, 10a)=11.1 Hz, J (1a, 6a)=10.1 Hz, J (1a, 10e)=4.3 Hz, 1H, Ha-1); 4.62 (ddd, J (3a, 4a)=11.7 Hz, J (3a, 4e)=2.2 Hz, J (3a, 14)=0.8 Hz, 1H, Ha-3); 6.86 (dd, J (14, 12)=1.5 Hz, J (14, 3a)=0.8 Hz, 1H, H-14); 7.11 (d, J (12, 14)=1.5 Hz, 1H, H-12). Spectrum NMR 13C (CDCl3): 77.65 (d, C-1); 72.07 (d, C-3); 49.54 (t, C-4); 70.52 (s, C-5); 51.82 (d, C-6); 22.89 (t, C-7); 34.20 (t, C-8); 31.36 (d, C-9); 41.22 (t, C-10); 146.74 (s, C-11); 121.72 (d, C-12); 108.88 (s, C-13); 126.11 (d, C-14); 21.16 (q, C-15); 22.02 (q, C-16). HR-MS: 345.0445 (M+, C15H21O2SBr+; calc. 345.0440).

Example 5. Synthesis of 4,7-dimethyl-2-(5-bromothiophene-2-yl)octahydro-2H-chromene-4-ol 1e

Similar to Example 1, interaction of 0.300 g isopulegol 2 with 0.37 g 5-bromothiophene-2-carbaldehyde in the presence of 1.4 g K10 clay during 120 min resulted in 0.512 g (yield 76%) of compound 1e.

Spectrum NMR 1H (CDCl3): 0.87-0.96 (m, 1H, Ha-8); 0.92 (d, J (16, 9a)=6.6 Hz, 3H, H-16); 1.02 (dddd, J (7a, 7e)=J (7a, 8a)=12.8 Hz, J (7a, 6a)=12.2 Hz, J (7a, 8e)=3.3 Hz, 1H, Ha-7); 1.09 (ddd, J (10a, 10e)=J (10a, 9a)=12.2 Hz, J (10a, 1a)=10.8 Hz, 1H, Ha-10); 1.25 (d, J (15, 4a)=0.8 Hz, 3H, H-15); 1.28 (ddd, J (6a, 7a)=12.2 Hz, J (6a, 1a)=10.2 Hz, J (6a, 7e)=3.3 Hz, 1H, Ha-6); 1.37-1.50 (m, 2H, Ha-9, OH); 1.72 (dm, J (8e, 8a)=12.8 Hz, others J<3.5 Hz, 1H, He-8); 1.81 (ddq, J (4a, 4e)=12.7 Hz, J (4a, 3a)=11.8 Hz, J (4a, 15)=0.8 Hz, 1H, Ha-4); 1.92 (dddd, J (7e, 7a)=12.8 Hz, J (7e, 6a)=J (7e, 8a)=J (7e, 8e)=3.3 Hz, 1H, He-7); 1.98 (dddd, J (10e, 10a)=12.2 Hz, J (10e, 1a)=4.3 Hz, J (10e, 9a)=3.7 Hz, J (10e, 8e)=2.0 Hz, 1H, He-10); 2.01 (dd, J (4e, 4a)=12.7 Hz, J (4e, 3a)=2.2 Hz, 1H, He-4); 3.24 (ddd, J (1a, 10a)=10.8 Hz, J (1a, 6a)=10.2 Hz, J (1a, 10e)=4.3 Hz, 1H, Ha-1); 4.59 (ddd, J (3a, 4a)=11.8 Hz, J (3a, 4e)=2.2 Hz, J (3a, 14)=0.8 Hz, 1H, Ha-3); 6.68 (dd, J (14, 13)=3.8 Hz, J (14, 3a)=0.8 Hz, 1H, H-14); 6.86 (d, J (13, 14)=3.8 Hz, 1H, H-13). Spectrum NMR 13C (CDCl3): 77.58 (d, C-1); 72.53 (d, C-3); 49.42 (t, C-4); 70.54 (s, C-5); 51.84 (d, C-6); 22.89 (t, C-7); 34.20 (t, C-8); 31.35 (d, C-9); 41.23 (t, C-10); 147.17 (s, C-11); 111.45 (s, C-12); 129.01 (d, C-13); 123.55 (d, C-14); 21.16 (q, C-15); 22.02 (q, C-16); HR-MS: 345.0442 (M+, C15H21O2SBr+; calc. 345.0440).

Example 6. Synthesis 4,7-dimethyl-2-(5-nitrothiophene-2-yl)octahydro-2H-chromene-4-ol 1f

Similar to Example 1, interaction of 0.400 g isopulegol 2 with 0.407 g 5-nitrothiophene-2-carbaldehyde in the presence of 1.6 g K10 clay during 60 min resulted in 0.400 g (yield 50%) of compound 1f.

Spectrum NMR 1H (CDCl3): 0.86-0.95 (m, 1H, Ha-8); 0.93 (d, J (16, 9a)=6.6 Hz, 3H, H-16); 1.01 (dddd, J (7a, 7e)=J (7a, 8a)=12.8 Hz, J (7a, 6a)=12.1 Hz, J (7a, 8e)=3.4 Hz, 1H, Ha-7); 1.09 (ddd, J (10a, 10e)=J (10a, 9a)=12.2 Hz, J (10a, 1a)=10.9 Hz, 1H, Ha-10); 1.26 (d, J (15, 4a)=0.7 Hz, 3H, H-15); 1.29 (ddd, J (6a, 7a)=12.1 Hz, J (6a, 1a)=10.2 Hz, J (6a, 7e)=3.2 Hz, 1H, Ha-6); 1.39-1.50 (m, 1H, Ha-9); 1.72 (dm, J (8e, 8a)=12.8 Hz, others J<3.5 Hz, 1H, He-8); 1.75 (ddq, J (4a, 4e)=12.8 Hz, J (4a, 3a)=11.9 Hz, J (4a, 15)=0.7 Hz, 1H, Ha-4); 1.92 (dddd, J (7e, 7a)=12.8 Hz, J (7e, 6a)=J (7e, 8a)=J (7e, 8e)=3.2 Hz, 1H, He-7); 1.99 (dddd, J (10e, 10a)=12.2 Hz, J (10e, 1a)=4.3 Hz, J (10e, 9a)=3.7 Hz, J (10e, 8e)=1.9 Hz, 1H, He-10); 2.04 (dd, J (4e, 4a)=12.8 Hz, J (4e, 3a)=2.2 Hz, 1H, He-4); 3.27 (ddd, J (1a, 10a)=10.9 Hz, J (1a, 6a)=10.2 Hz, J (1a, 10e)=4.3 Hz, 1H, Ha-1); 4.65 (ddd, J (3a, 4a)=11.9 Hz, J (3a, 4e)=2.2 Hz, J (3a, 14)=0.9 Hz, 1H, Ha-3); 6.82 (dd, J (14, 13)=4.2 Hz, J (14, 3a)=0.9 Hz, 1H, H-14); 7.75 (d, J (13, 14)=4.2 Hz, 1H, H-13). Spectrum NMR 13C (CDCl3): 77.81 (d, C-1); 72.38 (d, C-3); 49.42 (t, C-4); 70.25 (s, C-5); 51.68 (d, C-6); 22.78 (t, C-7); 34.09 (t, C-8); 31.25 (d, C-9); 41.04 (t, C-10); 154.79 (s, C-11); 150.56 (s, C-12); 128.17 (d, C-13); 121.75 (d, C-14); 21.01 (q, C-15); 21.95 (q, C-16 HR-MS: 311.1185 (M+, (C15H21O4NS)+; calc. 311.1186).

Example 7. Study of Analgesic Activity of Compounds of General Formula 1 in Acetic Acid Induced Writhing Test

Tests were carried out in outbred male mice with body mass 22-25 g. Experimental groups were formed, with 8 animals in each. <<Acetic writhes>> were produced by intraperitoneal administration of 0.75% acetic acid, 0.1 ml per animal. Test compounds were administered once intragastrically an hour before acetic acid administration. Animals that received only acetic acid were used as control. Activity was assessed by the quantity of writhes during 3 min.

The results are shown in Tables 2 and 4.

Compounds of general formula 1 were demonstrated to have potent analgesic activity in acetic acid induced writhing test.

Example 8. Studying the Analgesic Activity of Compounds of General Formula 1 in Hot Plate Test

Tests were carried out in outbred male mice of body mass 22-25 g. Experimental groups were formed, with 8 animals in each. The animals were placed on a copper hot plate, T=54° C. The effects were assessed by the duration of animal stay on the hot plate before the first <<vocalisation>>, in seconds.

Test compounds were administered once intragastrically an hour before the test. Control animals received the corresponding solvent. The results are shown in Tables 3 and 4. Compound of general formula 1a was demonstrated to have potent analgesic activity in hot plate test.

REFERENCES

  • 1. Mashkovsky M. D. Drugs. V. 1. M.: Medicine. 2007.
  • 2. Shubaev R. D., Mashkovsky M. D., Schwartz G. Y., Pokryshkin V. I. Comparative pharmacological activity of modern nonsteroidal anti-inflammatory drugs. Chem. Pharm. Journal. 1986. V. 20. No 1. P. 33-39.
  • 3. Vidal Reference book. Drugs in Russia: Reference book. M.: Astra Pharm Service. 2002. 3-90.
  • 4. Baishya G., Sarmah B., Hazarika N. Synlett 2013, Vol. 24, P. 1137-1141.

Read more
PatSnap Solutions

Great research starts with great data.

Use the most comprehensive innovation intelligence platform to maximise ROI on research.

Learn More

Patent Valuation

$

Reveal the value <>

30.0/100 Score

Market Attractiveness

It shows from an IP point of view how many competitors are active and innovations are made in the different technical fields of the company. On a company level, the market attractiveness is often also an indicator of how diversified a company is. Here we look into the commercial relevance of the market.

60.0/100 Score

Market Coverage

It shows the sizes of the market that is covered with the IP and in how many countries the IP guarantees protection. It reflects a market size that is potentially addressable with the invented technology/formulation with a legal protection which also includes a freedom to operate. Here we look into the size of the impacted market.

62.83/100 Score

Technology Quality

It shows the degree of innovation that can be derived from a company’s IP. Here we look into ease of detection, ability to design around and significance of the patented feature to the product/service.

29.0/100 Score

Assignee Score

It takes the R&D behavior of the company itself into account that results in IP. During the invention phase, larger companies are considered to assign a higher R&D budget on a certain technology field, these companies have a better influence on their market, on what is marketable and what might lead to a standard.

14.91/100 Score

Legal Score

It shows the legal strength of IP in terms of its degree of protecting effect. Here we look into claim scope, claim breadth, claim quality, stability and priority.

Citation

Patents Cited in This Cited by
Title Current Assignee Application Date Publication Date
Novel 5-heterocyclyl-chromane derivatives for the treatment of pain ASTRAZENECA AB,BESIDSKI, YEVGENI,GRAVENFORS, YLVA,KERS, INGER,NYLÖF, MARTIN 22 April 2008 30 October 2008
Method of preparing 4n-benzo/4,5/-cyclohepta-/1,2-b/ thiophene derivatives or salts thereof SANDOS A.G (FIRMA) 31 March 1975 28 February 1978
具有快速皮肤穿透速度的带正电荷的水溶性的芳基和杂芳基丙酸类前药 于崇曦,上海泰飞尔生化技术有限公司 15 August 2006 09 April 2014
See full citation <>

More Patents & Intellectual Property

PatSnap Solutions

PatSnap solutions are used by R&D teams, legal and IP professionals, those in business intelligence and strategic planning roles and by research staff at academic institutions globally.

PatSnap Solutions
Search & Analyze
The widest range of IP search tools makes getting the right answers and asking the right questions easier than ever. One click analysis extracts meaningful information on competitors and technology trends from IP data.
Business Intelligence
Gain powerful insights into future technology changes, market shifts and competitor strategies.
Workflow
Manage IP-related processes across multiple teams and departments with integrated collaboration and workflow tools.
Contact Sales
Clsoe
US9999613 2H-chromene derivatives analgesic agents 1 US9999613 2H-chromene derivatives analgesic agents 2 US9999613 2H-chromene derivatives analgesic agents 3